PharmaEssentia Corporation (TWSE: 6446)
Health Care · Biotechnology · TW
NT$1,195.00
+2.58% today · +153.5% 1Y
PharmaEssentia Corporation (TWSE: 6446) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.49B and employs 342 people.
Over the last twelve months the share price has gained 153.5%, trading between 407.92 and 1.65K.
Tweenvest scores PharmaEssentia Corporation across four factors: quality 73/100, value 31/100, growth 100/100, dividend 6/100. Its strongest factor is growth.
6446 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.49B
- Revenue (TTM)
- $652.27M
- P/E
- 64.60
- EPS
- 18.50
- Dividend yield
- 0.11%
- Beta (5Y)
- 0.65
- 52-week high
- NT$1,645.00
- 52-week low
- NT$407.92
- Avg volume (3M)
- —
- Shares outstanding
- 414.43M
- Employees
- 342
- Next earnings
- —
About PharmaEssentia Corporation
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
- ISIN
- TW0006446008
- Founded
- 1990
- Listed since
- Mar 11, 2014
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Incyte CorporationNasdaqGS: INCY | $22.86B | $112.79 | +0.04% |
| Insmed IncorporatedNasdaqGS: INSM | $21.97B | $100.60 | +0.12% |
| Genmab A/SCPSE: GMAB | $21.89B | Dkr2,445.00 | +3.78% |
| Innovent Biologics, Inc.SEHK: 1801 | $20.55B | HK$92.65 | +0.05% |
| Ascendis Pharma A/SNasdaqGS: ASND | $15.05B | $229.23 | +2.94% |
| Swedish Orphan Biovitrum AB (publ)OM: SOBI | $14.91B | Skr428.40 | +0.14% |
| Exelixis, Inc.NasdaqGS: EXEL | $14.83B | $59.86 | +1.42% |
| Neurocrine Biosciences, Inc.NasdaqGS: NBIX | $14.48B | $142.44 | +0.84% |
Figures last refreshed Oct 11, 2026.